A recent study suggests that individuals who stop using blockbuster slimming jabs like Mounjaro or Wegovy may regain lost weight far faster than those who halt traditional lifestyle regimens.
Findings released in a leading health publication shows that while obese people often shed substantial amounts of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing these drugs need to be aware of the risk of rapid rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
Such speed of recovery means a return to starting weight in about 18 months.
Analyzing Treatments
The research, which reviewed dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with other pills.
The team point out that people who lose weight through diet and exercise generally experience a slower creep back—around 0.1 kg a month—after stopping.
The Reason for the Quick Regain
Doctors suggest the way of the injections accounts for the heightened weight return.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone levels far above than normal could lead to the body to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making binge eating far more likely."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals contend that, due to the high risk of weight regain, the treatment might need to be long-term.
This perspective is reinforced by pharmaceutical companies, who state that the findings "emphasize the persistent nature of obesity," similar to managing conditions like hypertension.
User Accounts
People who have discontinued the jabs describe a sudden return of appetite.
"It was like a switch activating and you become extremely hungry," described a patient.
This difficulty is exacerbated if patients have not adopted sustainable dietary or behavioural modifications during treatment.
Growing Adoption
Survey data show that a significant number of people in the UK have used these injections in the past year, with desire remaining high.
- Adoption is higher among women compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone solution and lasting health benefits likely depends on combined behavioural management.
